Q-omics provides the consensus-scored DEFB1 profile across patient tissues and cancer cell-line models. DEFB1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, DEFB1 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, DEFB1 RNA expression shows 11,779 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight LUAD, COAD, and BRCA as cancer lineages where DEFB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB1 survival associations across molecular data types. DEFB1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB1 RNA expression–survival associations across cancer types. High DEFB1 expression shows unfavorable associations in LUAD, SCLC, PAAD, BRCA and CHOL, but favorable associations in HNSC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for DEFB1 RNA expression.
This table summarizes DEFB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DEFB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB1 shows lower tumor expression in COAD, KIRC, HNSC, KIRP and BRCA and higher tumor expression in LUSC. The COAD box plot shows higher DEFB1 RNA expression in normal versus tumor tissue (log2 FC = −3.681, t-test p < 0.001).
This table shows molecular features associated with DEFB1 in patient tissues and cancer cell lines. In patient samples, DEFB1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
